The Krembil Research Institute is pleased to welcome Dr. Martin Ingelsson as its newest Senior Scientist. Dr. Ingelsson is a geriatrician and neuroscientist with expertise in neurodegenerative diseases.
Dr. Ingelsson’s research is focused on characterizing the molecular mechanisms that underlie neurodegenerative diseases, such as Alzheimer disease, and developing strategies to diagnose and treat these conditions.
Prior to moving to Krembil, Dr. Ingelsson published a detailed characterization of the Uppsala mutation—a mutation in the amyloid precursor protein gene that leads to an early-onset form of Alzheimer disease. His study of this mutation has generated important insights into the formation of amyloid-beta, a peptide that accumulates in the brain of patients with Alzheimer disease.
“I am fascinated by the function of the brain and how dysregulation of molecular pathways can cause disease,” explains Dr. Ingelsson. “There is currently no effective treatment for Alzheimer disease, likely because of our limited understanding of its underlying mechanisms. It is thrilling to characterize disease-causing processes and develop strategies to counteract them.”
At Krembil, Dr. Ingelsson will continue to explore the causes of Alzheimer disease and other dementias. He will also explore biomarkers of neurodegeneration and work to develop treatments for dementia, with a focus on gene therapies.
Regarding his move to Krembil, Dr. Ingelsson comments that he looks forward to “...collaborating with the exceptional researchers at the institute to advance our understanding of devastating brain diseases and how to diagnose and treat them.”
Dr. Ingelsson earned his MD and PhD at the Karolinska Institute, where he was trained in the laboratory of Dr. Lars Lannfelt, and completed postdoctoral training with Dr. Bradley Hyman at Harvard Medical School. He has been a Professor at Uppsala University since 2016.
Welcome to Krembil, Dr. Ingelsson!
Dr. Ingelsson’s recruitment was made possible by a generous donation from the Krembil Foundation as part of the Krembil Strategic Research Plan Fund.